Integer Holdings Corporation $ITGR Stake Boosted by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS grew its stake in shares of Integer Holdings Corporation (NYSE:ITGR) by 6.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,000 shares of the medical equipment provider’s stock after purchasing an additional 400 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Integer were worth $861,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Intech Investment Management LLC grew its holdings in shares of Integer by 92.8% during the first quarter. Intech Investment Management LLC now owns 22,682 shares of the medical equipment provider’s stock valued at $2,677,000 after purchasing an additional 10,915 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Integer during the first quarter valued at approximately $916,000. Russell Investments Group Ltd. grew its holdings in shares of Integer by 14.7% during the first quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider’s stock valued at $796,000 after purchasing an additional 863 shares during the last quarter. Teacher Retirement System of Texas bought a new position in shares of Integer during the first quarter valued at approximately $579,000. Finally, Axiom Investors LLC DE bought a new position in Integer in the 1st quarter worth approximately $4,457,000. 99.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ITGR has been the subject of a number of recent analyst reports. Raymond James Financial decreased their price objective on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. Wells Fargo & Company decreased their price objective on Integer from $152.00 to $132.00 and set an “overweight” rating for the company in a report on Friday, July 25th. Weiss Ratings reissued a “hold (c)” rating on shares of Integer in a report on Wednesday, October 8th. Truist Financial decreased their price objective on Integer from $137.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Wall Street Zen upgraded Integer from a “hold” rating to a “buy” rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and an average target price of $137.29.

Integer Price Performance

Shares of NYSE:ITGR opened at $103.73 on Thursday. Integer Holdings Corporation has a one year low of $99.54 and a one year high of $146.36. The stock has a fifty day moving average of $104.99 and a 200-day moving average of $113.32. The company has a market capitalization of $3.63 billion, a PE ratio of 45.69, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same quarter last year, the company posted $1.30 EPS. Integer’s revenue was up 11.4% on a year-over-year basis. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, equities analysts anticipate that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.